Fresenius : Factsheet (PDF)

Factsheet H1 / 21

COMPANY PROFILE

Fresenius is a global health care group providing products and services for dialysis, hospitals and outpatient medical care. In addition, Fresenius focuses on hospital operations. We also manage projects and provide ­services for hospitals and other health care facilities. More than 310,000 employees have dedicated themselves to the service of health in over 100 countries worldwide.

FRESENIUS GROUP IN FIGURES

€ in millions	H1/ 21			H1 / 20		Change	FY/ 20
Sales and Earnings
Sales	18,230	18,055	1%		36,277
EBIT 1	2,039	2,248	-9%		4,612
Net income 1, 2	910	875	4%		1,796
Earnings per ord. share in € 1, 2	1.63	1.57	4%		3.22
Balance sheet and cash flow
Total assets	69,655				5%		66,646
Non-current assets	52,754				4%		50,874
Equity 3	27,131				4%		26,023
Equity ratio 3	39.0%					-	39.0 %
Net debt / EBITDA 1, 4	3.60				--		3.44
Investments 5	1,533	1,530	0%		3,300
Operating cash flow	2,103	3,960	-47%		6,549
Operating cash flow in %
of sales	11.5%	21.9%	--		18.1%
Profitability
EBIT margin 1	11.2%	12.5%	--		12.7%
Return on equity after taxes
(ROE) 1, 2	10.3%	10.5%	--		10.6%
Return on operating assets
(ROOA) 1	6.7%	7.4%	--		7.3%
Return on invested capital
(ROIC) 1	6.1%	6.6%	--		6.5%
Employees		312,734							311,269

1. Before special items
2. Net income attributable to shareholders of Fresenius SE & Co. KGaA
3. Including noncontrolling interests
4. LTM average exchange rates for both net debt and EBITDA; pro forma closed acquisitions / divestitures
5. Investments in property, plant and equipment, and intangible assets, acquisitions

GROUP STRUCTURE

The operating business comprises the four business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA.

32% 1

100%

100%

77%

Fresenius

Fresenius

Fresenius

Fresenius

Medical Care

Kabi

Helios

Vamed

1 As of June 30, 2021

BUSINESS SEGMENTS

€ in millions	H1 / 21			H1 / 20		Change		FY / 20
		Sales	8,530	9,045	-6%	17,859
		EBIT1	898	1,211	-26%	2,304
		Sales	3,516	3,467	1%	6,976
		EBIT2	574	581	-1%	1,095
		Sales	5,387	4,781	13%	9,818
		EBIT	566	472	20%	1,025
		Sales	1,033	974	6%	2,068
		EBIT		12	1	--	29

1 Reported

2 Before special items

• Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases. As of June 30, 2021 Fresenius Medical Care was treating 345,646 patients in 4,125 dialysis clinics. Along with its core business, the Renal Care Continuum, the company focuses on expanding in complementary areas and in the field of critical care.
• Fresenius Kabi offers intravenously administered generic drugs, clinical nutrition and infusion therapies for seriously and chronically ill patients. The company is also a leading supplier of medical devices and trans­ fusion technology products. In the biosimilars business, Fresenius Kabi develops products with a focus on oncology and autoimmune diseases.
• Fresenius Helios is Europe's leading private hospital operator and is active as a provider of reproduction medicine worldwide. Helios Ger- many operates 89 acute care hospitals, ~130 outpatient clinics and
  6 prevention centers. Quirónsalud operates 53 hospitals, including 6 in Latin America, 74 outpatient centers and ~ 300 occupational risk pre- vention centers.
• Fresenius Vamed manages projects and provides services for hospitals and other health care facilities worldwide and is a leading post-acute care provider in Central Europe. The portfolio ranges along the entire value chain: from project development, planning, and turnkey con- struction, via maintenance and technical management to total opera- tional management.

SALES BY REGION

Latin America and

Others 6%

Asia-Pacific10%

North America 38%

	SALES BY BUSINESS SEGMENT
	Fresenius Vamed
	5%
	Fresenius Kabi
	19%
Europe	46%
	Fresenius Helios
	29%
H1 / 21: € 18.2 billion	H1 / 21: €18.2 billion

Fresenius Medical Care

47%

Factsheet H1 / 21 © Fresenius SE & Co. KGaA - Investor Relations & Sustainability	Page 1 / 2

FRESENIUS SHARE / ADR			RELATIVE SHARE PRICE PERFORMANCE
			FRESENIUS SHARE VS. DAX
		Share
			125

Securities code no.	578 560
ISIN		DE0005785604
Ticker symbol		FRE
ADR CUSIP		35804M105
ADR Ticker symbol		FSNUY
Number of shares (June 30, 2021)	558,040,523
Market capitalization (June 30, 2021)		€24.6 billion

120

115

110

105

100

95

90

31.12.2020

31.01.2021

28.02.2021

31.03.2021

30.04.2021

31.05.2021

30.06.2021

			DAX		Fresenius share
ANALYST RECOMMENDATIONS	FINANCING MIX OF THE FRESENIUS GROUP

Sell 6%

Commercial Paper 6%

Equity-neutral convertible bonds 2%

Equal-weight / Hold / Neutral 22%

As of June 30, 2021

Accumulate / Add / Buy /

Outperform / 

Overweight 72%

Schuldschein loans 6%

Other financial liabilities 7%

Lease liabilities 23%

June 30, 2021: € 27,289 million

Bonds 56%

DEVELOPMENT OF DIVIDENDS IN €

									0.88
								0.84
							0.80
						0.75
					0.62
				0.55
		0.42	0.44
	0.37
0.32
2011	2012	2013	2014	2015	2016	2017	2018	2019	2020

GROUP OUTLOOK 2021

		FY / 20 Base1		Targets 2021 2
				Low-to-mid
				single-digit
Sales, growth (cc)				percentage
	€36,277 million		growth
				Low single-digit
Net income 3, growth (cc)				percentage
	€1,796 milion		growth

1. Before special items, including COVID-19 effects
2. Before special items, including estimated COVID-19 effects
3. Net income attributable to shareholders of Fresenius SE & Co. KGaA

For the outlook of the business segments please see the Investor News of July 30, 2021.

FINANCIAL CALENDAR

		Dates
Report on 3rd quarter 2021		November 2, 2021

Schedule updates, information on live webcasts, and other events at

www.fresenius.com/events-and-roadshows

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA

Registered Office: Bad Homburg, Germany

Commercial Register: Amtsgericht Bad Homburg, HRB 11852

Chairman of the Supervisory Board: Wolfgang Kirsch

General Partner: Fresenius Management SE

Registered Office: Bad Homburg, Germany

Commercial Register: Amtsgericht Bad Homburg, HRB 11673

Management Board: Stephan Sturm (Chairman), Dr. Sebastian Biedenkopf, Dr. Francesco De Meo, Rachel Empey, Rice Powell, Michael Sen, Dr. Ernst Wastler

Chairman of the Supervisory Board: Wolfgang Kirsch

CONTACT

Fresenius SE & Co. KGaA Else-Kröner-Straße1, 61352 Bad Homburg v. d. H. e-mail: [e-mail]

Internet: www.fresenius.com

Markus Georgi
Senior Vice President	Telephone:	[phone]
Investor Relations & Sustainability	Telefax:	[phone]
Follow us:

Factsheet H1 / 21 © Fresenius SE & Co. KGaA - Investor Relations & Sustainability	Page 2 / 2